课题基金 / 基金详情

项目摘要

项目成果

DENISE R. ABERLE的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT The landmark NLST demonstrated a 20% mortality reduction in lung cancer in individuals who underwent low dose computed tomography (LDCT) screening relative to plain chest radiography. The results of the NLST have resulted in a sea change in US health policy, such that third party payers and Medicare now provide LDCT screening as a preventive service benefit in eligible, high risk smokers. Understanding the factors underlying tumor indolence or aggression that result in heterogeneous clinical outcomes, may facilitate clinical decision making in the context of lung cancer screening and thereby greatly increase its effectiveness. We hypothesize that the mutational landscape of screen-detected lung cancers is an important contributor to their indolence or aggressiveness. To address this hypothesis we will take advantage of the comprehensively annotated NLST biorepository. Whole exome sequencing (WES) of the previously collected NLST samples will be performed to determine the genomic features that distinguish between screen-detected indolent and aggressive lung tumors that result in heterogeneous clinical outcomes. Samples from 110 patients with aggressive cancers and 494 with indolent cancers along with matching reference tissues will be assessed. By utilizing WES, we will be able to identify the impact of genes not previously associated with lung cancer as well as novel alleles of genes with known roles in lung cancer. This will be the first comprehensive genomic characterization of aggressive and indolent lung cancers diagnosed in the course of a lung cancer screening trial. The detailed genomic and imaging-based characterization of screen-detected tumors will ultimately impact clinical management of those cancers. Through separate funding, we will also integrate the genomic data obtained through this research with the tumor immune microenvironment (as characterized by multiplex immunofluorescence analysis of the same specimens) and CT imaging features to build integrated, multiparametric models of tumor biology that can be used to predict the biological behavior of lung cancers in the screening setting.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
Drug Development for Metastasis Prevention.
预防转移的药物开发。
DOI: 10.1615/critrevoncog.v20.i5-6.150
发表时间: 2015
期刊: Critical reviews in oncogenesis
影响因子: --
作者: [Fontebasso Y, Dubinett SM]
通讯作者: Dubinett SM
DOI: 10.1186/s13059-017-1191-5
发表时间: 2017-03-24
期刊: Genome biology
影响因子: 12.3
作者: [Kang S, Li Q, Chen Q, Zhou Y, Park S, Lee G, Grimes B, Krysan K, Yu M, Wang W, Alber F, Sun F, Dubinett SM, Li W, Zhou XJ]
通讯作者: Zhou XJ
DOI: 10.1158/2159-8290.cd-20-1087
发表时间: 2020-10
期刊: Cancer discovery
影响因子: 28.2
作者: [Krysan K, Tran LM, Dubinett SM]
通讯作者: Dubinett SM
DOI: 10.1016/j.ctarc.2021.100486
发表时间: 2021
期刊: Cancer treatment and research communications
影响因子: --
作者: [Burks EJ, Zhang J, Sullivan TB, Shi X, Sands JM, Regis SM, McKee BJ, McKee AB, Zhang S, Liu H, Liu G, Spira A, Beane J, Lenburg ME, Rieger-Christ KM]
通讯作者: Rieger-Christ KM
Individually-tailored clinical decision support for management of indeterminate pulmonary nodules
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer
EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer Assessment
EFIRM-Liquid Biopsy (eLB): Ultrasensitive ctDNA and miRNA Detection for Early Assessment of Lung Cancer